Pfizer, BioNTech say bivalent COVID-19 booster shot performs better against BA.5 omicron subvariant - ABC News
Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What
DPH Shares Monthly COVID-19 Update, Announces Changes to Data Reporting and Booster Guidance - State of Delaware News
Why and When to Get a Bivalent Covid-19 Booster | Johns Hopkins | Bloomberg School of Public Health
Potentially breaking the COVID-19 stalemate with variant booster, bivalent or polyvalent vaccines
COVID-19 BIVALENT BOOSTER EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION - CROI Conference
The Updated COVID Boosters Could Have Been Better | MedPage Today
New Omicron-specific vaccines offer similar protection to existing boosters
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
CDC publishes first estimates of bivalent boosters' effectiveness against XBB.1.5
Effectiveness of Bivalent Boosters against Severe Omicron Infection | NEJM
COVID-19 bivalent booster effectiveness in people with and without immune dysfunction L
Bivalent Moderna vaccine effective against Omicron sub-variants - Hospital Pharmacy EuropeHospital Pharmacy Europe
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
Boosting with updated COVID-19 mRNA vaccines | Nature Medicine
Updated boosters add limited protection against Covid-19 illness, first real-world study shows | CNN
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a
Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study - The Lancet Infectious Diseases
